科兴制药: 关于以集中竞价交易方式回购公司股份的进展公告

Core Viewpoint - The company has announced a share buyback plan with a budget of between 30 million and 60 million RMB, aimed at employee stock ownership plans or equity incentives, with a buyback period from March 17, 2025, to March 16, 2026 [1] Buyback Plan Details - The buyback plan was approved on March 17, 2025, allowing the company to repurchase shares through the Shanghai Stock Exchange [1] - The total amount already repurchased is 4,738.19 million RMB, with a total of 1,269,333 shares bought back, representing 0.64% of the total share capital [2] - The buyback price range has been adjusted, with the maximum price set at 46.83 RMB per share initially, later revised to 46.75 RMB after the annual equity distribution [2] Progress of Buyback - As of June 30, 2025, the company has completed the buyback of 1,269,333 shares at prices ranging from 23.14 RMB to 43.50 RMB per share [2][3] - The total funds used for the buyback, excluding transaction fees, amount to 4,738.19 million RMB [2]